Drug Trial Radar · NCT06493799
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
226
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Mar 31, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Green Cross WellbeingIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
Conditions
- Chronic Liver Disease
Interventions
LAENNEC (Human Placenta Hydrolysate) IVDrug
Intravenous Injection
LAENNEC (Human Placenta Hydrolysate) SCDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ALT level relative to baseline at 6 weeksTime frame: week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GC wellbeing
Yongin-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.